Acceleron Pharma Initiates First-in-Human Study Of ACE-041, A Novel Angiogenesis Inhibitor, In Patients With Advanced Cancer

Links shared publicly online about this topic.

  • 1,623
    total visits

Acceleron Pharma Initiates First-in-Human Study Of ACE-041, A Novel Angiogenesis Inhibitor, In Patients With Advanced Cancer

medicalnewstoday.com —

Acceleron pharma, inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, a

View full resource at medicalnewstoday.com

Tags: Cancer, Muscle, Bone, Fat, Pharma

  • Share

Most Recently Shared on November 6, 2009 at 5:24 am By:

Health_Feed Health Feed

#HEALTH Acceleron Pharma Initiates First-in-Human Study Of ACE-041, A Novel Angiogenesis Inhibitor, In Patients Wit... http://ow.ly/15ZNQr

3 years ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Cancer News MNT Cancer News

Advertisement